Association of pretreatment body mass index and survival in human papillomavirus positive oropharyngeal squamous cell carcinoma.

Oral oncology

PubMedID: 27531873

Albergotti WG, Davis KS, Abberbock S, Bauman JE, Ohr J, Clump DA, Heron DE, Duvvuri U, Kim S, Johnson JT, Ferris RL. Association of pretreatment body mass index and survival in human papillomavirus positive oropharyngeal squamous cell carcinoma. Oral Oncol. 2016;6055-60.
BACKGROUND
Pretreatment body mass index (BMI) >25kg/m(2) is a positive prognostic factor in patients with head and neck cancer. Previous studies have not been adequately stratified by human papilloma virus (HPV) status or subsite. Our objective is to determine prognostic significance of pretreatment BMI on overall survival in HPV+ oropharyngeal squamous cell carcinoma (OPSCC).

METHODS
This is a retrospective review of patients with HPV+ OPSCC treated between 8/1/2006 and 8/31/2014. Patients were stratified by BMI status (>/<25kg/m(2)). Univariate and multivariate analyses of survival were performed.

RESULTS
300 patients met our inclusion/exclusion criteria. Patients with a BMI >25kg/m(2) had a longer overall survival (HR=0.49, P=0.01) as well as a longer disease-specific survival (HR=0.43, P=0.02). Overall survival remained significantly associated with high BMI on multivariate analysis (HR=0.54, P=0.04).

CONCLUSIONS
Pre-treatment normal or underweight BMI status is associated with worse overall survival in HPV+ OPSCC.